BeiGene: Forward-looking layout, steady and steady winning model

Due to the different corporate genes and resource conditions, the development models of different companies have certain differences.
BeiGene has the characteristics of advance layout and step-by-step operation, high-profile construction of R&D, production operations and commercialization teams, and the pursuit of heavyweight products and internationalization.
As a guide, we have promoted the research and development of innovative drugs in accordance with international standards, and won the favor of the world's top investment and multinational pharmaceutical companies, embarking on a unique development path
.

In the history of the rise of China's biomedical industry, BeiGene is a good research sample that can be used for reference by many investment institutions and innovative drug companies
.

CEO of BeiGene Bio-Island Innovation Center-Dr.
Liu Jian

With our curiosity and learning mentality, the "Innovation · China Tour" team conducted in-depth study and discussion with Dr.
Liu Jian, CEO of BeiGene Bio-Island Innovation Center
.

A delegation from Biomedicine "Innovative Power · China Tour" visited BeiGene Guangzhou Bio-Island Innovation Center

Confidence comes from a strong product pipeline

Confidence comes from a strong product pipeline

Dr.
Liu Jian introduced to us that whether it is an investor or an enterprise employee, everyone has confidence in BeiGene, and the most important thing is that BeiGene has the ability to develop potential blockbuster products with international standards
.

BeiGene is a company with a development mission of "establishing a new generation of biopharmaceutical companies, using our courage, continuous innovation, challenging the status quo, and letting the highest quality treatment solutions benefit billions of people around the world"
.

Therefore, whether it is completely independent research and development, or introduction and development, BeiGene is guided by saving the lives of patients around the world and developing products according to the highest international standards

Among the innovative pharmaceutical companies, BeiGene has done more in-depth longitudinal research.
The targets developed independently have better differentiated designs and have the potential for clinical superiority.
At the same time, they always maintain a deep focus on anti-tumor drugs
.

Taking the BGB-3111 Zebutinib (Baiyueze), which passed the test of 3111 compounds, as an example, the BeiGene team aimed at the first-generation BTK inhibitor ibrutinib that could not completely, lasting and accurately inhibit BTK.
With these defects as the starting point to optimize the compound structure, with the optimized drug structure, it can inhibit the target more accurately, can form a complete and lasting deep inhibition of BTK, and reduce the adverse reactions caused by off-target effects.
Thus designed a new generation of BTK inhibitor Zebutinib
.

With its differentiated pharmacokinetics from other approved BTK inhibitors, Zebutinib can more effectively inhibit the proliferation of malignant B cells in multiple disease-related tissues

BGB-3111

A better drug structure brings more significant clinical value
.

On November 15, 2019, the U.

The pursuit of better drug structure and clinical value is also reflected in tislelizumab (Bezan)
.

Tilelizumab "is a humanized lgG4 anti-programmed death receptor 1 (PD-1) monoclonal antibody, designed to minimize binding to Fcγ receptors in macrophages
.

Clinically.

From the perspective of clinical data, the approval of tislelizumab for marketing is based on the clinical research results of a single-arm, multi-center, pivotal phase 2 clinical trial BGB-A317-203 in China, based on the independent review committee The objective response rate (ORR) evaluated by (IRC) was 76.
9%, of which the complete response (CR) rate was 61.
5%
.

The clinical value of tislelizumab is also reflected in its commercial value
.

According to BeiGene's 2020 financial report, even under the influence of the new crown epidemic, since tislelizumab was listed in China in March 2020, its annual sales were 163.

BeiGene's other products also have advantages in drug structure and clinical value
.

BeiGene 's TIGIT antibody BGB-A1217 retains the Fc effector necessary for anti-tumor activity
.

Dr.

BGB-A1217

According to Dr.
Liu, BeiGene ’s OX40 antibody BGB-A445 is currently the only OX40 antibody that does not block the binding of OX40L
.

OX40 is an important T cell costimulatory molecule and a member of the tumor necrosis factor receptor (TNF) superfamily

BGB-A445

Excellent clinical value depends on the world's top scientific research

Excellent clinical value depends on the world's top scientific research

Through ten years of development, BeiGene has established a scientific research system with a forward-looking and international perspective
.

BeiGene will now expand its layout in the early stage of target discovery, because cutting in from an earlier stage can greatly enhance the global competitiveness of the drug, and even have the opportunity to make a first-in-class drug
.

There are some projects that did not even have any clinical data verification when they were launched.

BeiGene has two principles for the selection of targets
.
First of all, this target has been supported by clear data on proof of concept, but there may not already be drugs on the market; secondly, scientists must have a full understanding of the target and compound, and know which aspects It can be differentiated and has the potential to be "best-in-class"
.

Agile decision-making is one of the latecomer advantages of emerging biomedical companies
.
BeiGene has given full play to its advantages as an innovative biotechnology company, conducted decision-making communication with extremely high efficiency, and quickly pushed forward the project
.
For example, it only took more than 2 years for Baiyueze® from the establishment of the project to the first patient's administration, which fully proved the professionalism and efficiency of this R&D team
.

In innovation work, talents are the first resource
.
Under the guidance of advanced concepts and cutting-edge perspectives, BeiGene has now established a team of more than 2,000 scientists and clinical medical experts around the world
.
The high quality of this R&D team is not only reflected in the fact that most of its members have overseas study experience, but also because they can keenly capture global scientific research trends and have strong R&D execution capabilities
.

Under the guidance of the spirit of science, BeiGene established a scientific advisory committee
.
This is a team of world-leading academic experts including the National Academy of Sciences, the American Cancer Institute, and Stanford University.
It provides basic research results for BeiGene's in-depth research and understanding of diseases and targets, and contributes to the company's research and development.
Escort the direction
.

Thanks to this global layout, BeiGene related clinical trials can be carried out in more than 40 countries and regions.
In addition to the domestic domestic market, it also covers developed markets such as Europe, the United States, and Japan, as well as Eastern Europe, Asia Pacific, etc.
Developing country markets
.

International standard production and operation management is an important guarantee for Baekje's global development

International standard production and operation management is an important guarantee for Baekje's global development

Similar to the scientific research layout, BeiGene's production and operations are also forward-looking in accordance with the highest international standards
.

BeiGene Guangzhou Sino-Singapore Knowledge City Production Base

For example, the Guangzhou macromolecular biopharmaceutical production base located in the Sino-Singapore Guangzhou Knowledge City, adhering to the construction goal of "global quality, global supply", and in accordance with the GMP quality management standards of China, the United States and the European Union, has established a set of internationally leading quality standards.
Management system
.

When talking about the forward-looking high-standard construction of BeiGene Guangzhou Base, Dr.
Liu Jian shared the tremendous pressure he faced when making major decisions
.
In 2017, when BeiGene's macromolecular biopharmaceuticals had not yet been approved, the development prospects were still unclear and BeiGene was under financial pressure, unlike other companies' gradual upgrade decisions, Dr.
Liu Jian made a decision in accordance with global standards.
, Decided to invest 2.
3 billion yuan to build 24,000 liters of production capacity in one step
.
This decision is under tremendous pressure at the company's high-level collective decision-making meeting, and even to a certain extent it is a bet on Dr.
Liu Jian's career
.
Up to now, BeiGene’s huge demand for macromolecular drugs proves that Dr.
Liu Jian’s judgment on the market prospects of domestic and international companies’ products at the time was accurate.
Upgrade investment to reduce overall costs, and help improve product competitiveness
.

Dr.
Liu Jian introduced: “Beijing Shenzhou has formulated a complete project quality management system in accordance with the standards of international pharmaceutical engineering, and through a series of regulations and training, to create a quality first culture, it can be said that our Guangzhou biopharmaceutical production The base, whether it is hardware or software, is at the world's leading level
.
" At present, the Guangzhou base is accelerating the construction of automation and artificial intelligence, including the introduction of augmented reality smart glasses, digital twins and research and development of artificial intelligence, three-dimensional modeling and modular design and other new technologies , Empowering the construction of smart factories
.

BeiGene Guangzhou Bio-Island Innovation Center

In accordance with the same international standards, BeiGene's Suzhou Innovative Drug Industrialization Base has also started construction
.
The newly-built base will have the ability to fully meet the company's existing small molecule commercial products and future clinical R&D pipeline clinical products, significantly improve independent production and late-clinical drug R&D capabilities, and help the company's global strategic layout of innovative anti-cancer drugs
.

The first-class commercialization team is also one of the important factors for stakeholders to have confidence in BeiGene

The first-class commercialization team is also one of the important factors for stakeholders to have confidence in BeiGene

For innovative pharmaceutical companies, whether they can do a good job in commercialization is a very important test
.

Unlike many companies that are slower in commercialization, BeiGene started commercialization early in the morning
.
In 2018, BeiGene welcomed the industry's star manager-Wu Xiaobin, who has experience in China business leadership of multinational companies such as Pfizer, Bayer, and Wyeth, joined, and began BeiGene's China and global commercial deployment
.

So far, BeiGene has established a commercial team of more than 2,000 people in China, and the team is still expanding
.
BeiGene believes that for innovative pharmaceutical companies, the future stage must be globally, and Chinese innovative pharmaceutical companies will also stand on the global stage to compete with multinational pharmaceutical companies
.

In addition to expanding its workforce in the traditional sense, BeiGene also keeps pace with the times, adopting technologies including the Internet and digitization, conducting online education, and strengthening commercialization
.

In terms of international commercialization, BeiGene mainly uses strategic cooperation, and the partners selected are the world's top pharmaceutical companies
.
At present, it has reached cooperation with Novartis to develop and commercialize the anti-PD-1 antibody tislelizumab.
Novartis will jointly develop and commercialize tislelizumab in North America, Japan, the European Union and six other European countries.
Jeshenju received an advance payment of US$650 million and was eligible for potential registration and sales milestone payments of up to US$1.
55 billion, as well as product sales royalties, with a total transaction value of more than US$2.
2 billion
.

Reporter's essay

There can be no shortcomings in the corporate value chain
.
From the product point of view, the value chain processes from R&D, production to commercialization, as well as the internal processes of each function are mostly linear processes.
Failure to do the best in each link may adversely affect the final value, or even seriously affect value creation.
As a result, the product cannot reach the expected goal, therefore, the value chain cannot have any shortcomings
.
According to Dr.
Liu Jian, BeiGene has established a whole-industry value chain system from R&D, production to commercialization, and established its own core competitiveness in a specific field
.

Corporate culture is often the internal driving force for corporate value creation
.
In BeiGene, everyone has the same mission, vision and goal-to make innovative drugs of high quality, effective and affordable to benefit more than 2 billion people around the world
.
In innovative drug companies, especially those that are dominated by tumor diseases, this should be the inner driving force that most motivates employees to fight for it
.